Korsana Biosciences (CYCN) SEC Filings, Jun-Aug 2025

Cyclerion Therapeutics, Inc. (CYCN) reported that Chief Financial Officer Rhonda M. Chicko was granted an option to purchase 25,000 shares of common stock at an exercise price of $2.355 per share. The grant, reported with a transaction date of 08/07/2025, is under the 2019 Equity Incentive Plan. Of the 25,000 shares, 8,750 are immediately exercisable and 16,250 vest in monthly installments beginning August 31, 2025 and ending February 28, 2028, subject to continued service. The option expires August 6, 2035, and the reporting person is shown as the direct beneficial owner of the 25,000 option shares following the transaction.